BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s share price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $58.50 and traded as high as $58.65. BioMarin Pharmaceutical shares last traded at $58.51, with a volume of 2,252,110 shares.
Wall Street Analyst Weigh In
BMRN has been the subject of a number of analyst reports. Piper Sandler boosted their target price on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 1st. Jefferies Financial Group raised their price target on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Raymond James Financial raised BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price target for the company in a report on Monday, October 12th. Canaccord Genuity Group lifted their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Royal Bank Of Canada lowered their price objective on BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.22.
Read Our Latest Analysis on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
The company has a current ratio of 2.44, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market cap of $11.90 billion, a price-to-earnings ratio of 34.51, a PEG ratio of 0.82 and a beta of 0.21. The stock’s 50 day moving average is $58.42 and its two-hundred day moving average is $58.54.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the business posted $0.12 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% on a year-over-year basis. Analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.20 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other BioMarin Pharmaceutical news, EVP Gregory Friberg sold 5,147 shares of the business’s stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $58.81, for a total value of $302,695.07. Following the transaction, the executive vice president directly owned 42,585 shares of the company’s stock, valued at approximately $2,504,423.85. The trade was a 10.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.68% of the stock is currently owned by company insiders.
Institutional Trading of BioMarin Pharmaceutical
Several hedge funds have recently made changes to their positions in BMRN. Amundi raised its holdings in BioMarin Pharmaceutical by 37.8% during the second quarter. Amundi now owns 259,782 shares of the biotechnology company’s stock worth $14,865,000 after purchasing an additional 71,246 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in BioMarin Pharmaceutical during the second quarter worth $3,461,000. Rice Hall James & Associates LLC purchased a new stake in BioMarin Pharmaceutical during the second quarter worth $14,203,000. Bank of New York Mellon Corp purchased a new stake in BioMarin Pharmaceutical during the second quarter worth $66,107,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at $39,312,000. Institutional investors and hedge funds own 98.71% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
See Also
- Five stocks we like better than BioMarin Pharmaceutical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
